-
Home > News
News
-
Press Releases
- November 7, 2011
- Naurex’s Novel Antidepressant GLYX-13 Recognized as One of Windhover’s 2011 Top 10 Neuroscience Projects to Watch
- June 22, 2011
- Naurex Initiates Phase II Clinical Trial of Novel Antidepressant GLYX-13 In Treatment-Resistant Depression
- May 11, 2011
- Naurex Completes $18 Million Series A Financing
- December 7, 2010
- New Preclinical Data Confirm Naurex’s Novel Antidepressant GLYX-13 Appears Free of the Behavioral Impairment and Abuse Potential Seen With Ketamine
- November 17, 2010
- Preclinical Data at Neuroscience 2010 Show Naurex's Novel Antidepressant GLYX-13 Shares Key Efficacy Mechanisms With Ketamine
- August 31, 2010
- Naurex’s Novel Antidepressant GLYX-13 Recognized as One of Windhover's Top 10 Neuroscience Projects to Watch
- June 17, 2010
- Naurex Inc. Presents Positive Clinical Data on Novel Mechanism Antidepressant Candidate GLYX-13 at NCDEU 50th Anniversary Meeting
- February 11, 2010
- Naurex Inc. Reports Positive Top-Line Phase I Results for its Novel Mechanism NMDA Receptor Modulator GLYX-13 in Treatment-Resistant Depression
- December 16, 2009
- Naurex Inc. Announces Presentation of Preclinical Data Showing its Novel Mechanism NMDA Modulator Exhibits Robust and Rapid-Onset Antidepressant Activity with No Signs of Classic NMDA-Associated Side Effects
- December 16, 2009
- Naurex Inc. Initiates Phase I Clinical Trial of its Novel Mechanism NMDA Modulator GLYX-13 in Treatment-Resistant Depression
Naurex in the News
- Profile: Naurex Inc.: Prepping a peptide as an antidepressant, March 2011 - Start-Up (Subscription required)
- Company Spotlight: Naurex, July/ August 2010 - NeuroInvestment (Subscription required)
- Naurex Inc. Presents Positive Clinical Data on Novel Mechanism Antidepressant Candidate GLYX-13, June 17, 2010 - Bloomberg Businessweek
- Naurex Opens the Therapeutic Window for NMDA Modulators, December 29, 2009 - BioWorld Today (Subscription required)